Melanotan 1

The free-injection form (research chemical, SubQ): plasma half-life approximately 33 minutes from the rapid absorption and distribution phase (Dorr et al., 1996 — the Arizona cl…

Nle4: leucine at position 4 replaced with norleucine — increases metabolic stability; D-Phe7: natural L-phenylalanine at position 7 replaced with D-phenylalanine — improves receptor binding geometry and dramatically increases potency. Together these modifications make afamelanotide 100 to 1,000 times more potent than native α-MSH in bioassays (FDA pharmacology review, NDA 210797) and extend its plasma half-life from under 8 minutes (native α-MSH) to approximately 33 minutes for free injection — or approximately 15 hours apparent half-life from the controlled-release SCENESSE implant.

Erythropoietic protoporphyria (EPP) is a rare autosomal recessive genetic disorder caused by partial deficiency of the enzyme ferrochelatase (FECH). The deficiency causes massive accumulation of protoporphyrin IX (PPIX) in skin, red blood cells, and liver. When light hits PPIX in the skin — including visible light at 400-410 nm, not just UV — it acts as a photosensitizer generating reactive oxygen species. The result: excruciating burning pain beginning within minutes of sun exposure, lasting hours or days, entirely unresponsive to analgesics. There is no dosing the pain away. EPP patients develop profound sun-avoidance behavior from early childhood. Many cannot attend outdoor events, sports, summer activities, or ordinary daytime life. Vitamin D deficiency and osteoporosis from sun avoidance are common sequelae. Before SCENESSE, there was no effective treatment — only avoidance.

MC1R agonism drives eumelanogenesis — the production of brown-black eumelanin — without requiring UV exposure. The eumelanin acts as a broad-spectrum optical filter and antioxidant shield, absorbing and scattering visible light and quenching free radicals before PPIX-generated ROS reach sufficient concentration to trigger the pain response. The pivotal NEJM trials (Langendonk et al., 2015): two multicenter RDBPCs, 16 mg SC implant; patients went from a median of 41 hours of pain-free direct sunlight over 180 days at baseline to 64 hours on afamelanotide (vs 40 hours on placebo). In real-world practice (Wensink et al., JAMA Dermatology, 2020) the effect was larger than in trials — patients gained a median of 6 additional hours per week outdoors. Quality of life scores improved from 31% to 74% of maximum.

FDA approval: October 8, 2019. NDA 210797. Orphan Drug designation. Priority Review. Indication: increase pain-free light exposure in adult patients with a history of phototoxic reactions from EPP. EMA: conditional authorization December 2014. September 2025: label amendment approved year-round use (every 2 months without annual limit of 4 implants). Orphan exclusivity expired December 2024 (10-year period ended). Clinuvel Pharmaceuticals, Burlingame CA.

The fitness, aesthetic, and biohacking community uses Melanotan 1 primarily for cosmetic tanning — a pharmacologically real effect that the community can achieve via self-injected research chemical powder. This is off-label, unmonitored, and uses a different delivery form from the controlled-release SCENESSE implant. The medical use is for a devastating rare disease in a formally monitored clinical setting with a specific disease-state rationale. The gap between these two uses is the central tension of this chapter: same compound, radically different contexts, radically different oversight.

MT1 (afamelanotide) binds: MC1R (very high affinity — primary; drives melanogenesis); MC3R, MC4R, MC5R (lower affinity; functional at higher doses). MT2 (melanotan II) binds all five MCRs with high potency and is a cyclic heptapeptide — shorter, more conformationally rigid, and non-selective. The critical difference: MC4R activation is what drives MT2's CNS effects (appetite suppression, spontaneous erection, libido, nausea, behavioral effects). MT1 is much more MC1R-selective. Community experience: MT1 produces tanning without the sexual arousal, appetite suppression, or severe nausea that characterizes MT2 use. It is not 'MT2 but milder' — it is a meaningfully different receptor profile.

The FDA prescribing information for SCENESSE explicitly warns that afamelanotide 'may induce darkening of pre-existing nevi and ephelides' and recommends 'a regular full body skin examination (twice yearly) to monitor all nevi and other skin abnormalities.' This is not an academic precaution — nevi darkening is documented in treated EPP patients in multiple studies. The melanoma risk question is more nuanced: a 2021 dermoscopic study (Arisi et al.) found that afamelanotide-induced nevi changes in 15 EPP patients were transient and physiologically normal. The Biolcati 2015 long-term observational study argued that MC1R signaling is INVERSELY associated with melanoma risk — low MC1R activity variants are associated with higher sporadic melanoma. However, the Habbema 2017 review documented 4 case reports of melanoma temporally associated with unregulated melanotan use — confounded by product purity, UV-seeking behavior, and inability to establish causality. Active melanoma: absolute contraindication.

Not listed on the 2026 WADA Prohibited List. MT1/afamelanotide is not a performance-enhancing drug under anti-doping frameworks. However, it is an FDA-approved prescription drug — sourcing it as a research chemical for cosmetic use is off-label, outside the approved delivery system, and outside the monitoring infrastructure the approved use requires.